Overview: Cancer CNS Tumor Gene Panel
Introduction: The Cancer CNS Tumor Gene Panel is a diagnostic tool designed to screen for CNS tumor mutations using FFPE tissue samples. In India, central nervous system tumors (gliomas, meningiomas) have incidence ~2-5 per 100,000, with gliomas (glioblastoma) most aggressive. Key mutations (IDH1/2, TP53, ATRX, TERT, H3F3A, BRAF) guide WHO classification, prognosis, and targeted therapy (e.g., IDH inhibitors). High morbidity from underdiagnosis in rural areas, limited neurosurgery/NGS access, delayed molecular classification leading to suboptimal treatment. Per molecular pathology practices aligned with ICMR and Neurological Society of India guidelines, the test employs NGS for mutation analysis over 1-2 days with high sensitivity/specificity, valuable for precision neuro-oncology. This diagnostic falls under genetic cancer screening and targets CNS tumor tissue, addressing accurate detection to guide therapy and prognosis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise treatment and improving survival. Its FFPE-based approach ensures reliable detection.
Other Names: CNS Tumor Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.
Historical Milestone: IDH/TERT/BRAF profiling; in India, growing in neuro-oncology centers.
Purpose: The test screens for 7 parameters including IDH1 to guide CNS tumor assessment, classify molecular subtype, inform targeted therapy.
Test Parameters: 1. IDH1, 2. IDH2, 3. TP53, 4. ATRX, 5. TERT, 6. H3F3A, 7. BRAF.
Pretest Condition: No fasting required; patients should have confirmed CNS tumor diagnosis with FFPE tissue available.
Specimen: FFPE tissue block (0.5-2 cm³), transported within specified times to maintain sample viability.Sample Stability: Indefinite when properly stored (paraffin-embedded blocks stable long-term).
Medical History: Patients should provide details on tumor type, symptoms (headache, seizures), prior therapy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated mutations including poor prognosis, benefits of profiling, and minimal discomfort (tissue already collected).
Procedural Considerations: The test involves sample processing using NGS by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Poor tissue quality, low tumor content, or delays can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Actionable mutations indicate prognosis/therapy options, necessitating specialist input. No mutations may require follow-up.
Specialist Consultation: Neuro-oncologists or neurosurgeons should be consulted for management.
Additional Supporting Tests: MRI, IHC for confirmation.
Test Limitations: Covers selected genes; comprehensive approach required.
References: Indian Journal of Neurosurgery 2024, CNS Tumor Studies India 2023.
